Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): A qualitative analysis of clinical studies in patients with Alzheimer's disease

International Journal of Clinical Practice

Volumn 69, Issue 5, 2015, Pages 518-530

  Alva, G ^a   Cummings, J L ^b   Galvin, J E ^c   Meng, X ^d   Velting, D M ^d  

^a ATP Clinical Research   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIVASTIGMINE; NEUROPROTECTIVE AGENT;

ADULT; AGED; ALZHEIMER DISEASE; APPLICATION SITE DERMATITIS; APPLICATION SITE DISCOLORATION; APPLICATION SITE DRYNESS; APPLICATION SITE ECZEMA; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE SWELLING; APPLICATION SITE VESICLE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INJECTION SITE EROSION; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE INDURATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SKIN EXFOLIATION; SKIN MANIFESTATION; CUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; DRUG ERUPTIONS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; AGED; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; INCIDENCE; MALE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVASTIGMINE; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH;

EID: 84928585596     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12621     Document Type: Article

References (22)

1. Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006; 67: 657-64.
2. Priano L, Gasco MR, Mauro A,. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23: 357-75.
3. Ale I, Lachapelle JM, Maibach HI,. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009; 26: 920-35.
4. Rivastigmine patch (Exelon Patch®) US Prescribing Information 2013. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf (accessed 24 July 2014).
5. Winblad B, Machado JC,. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008; 5: 1377-86.
6. Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013; 19: 745-52.
7. 2) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 341-53.
8. Farlow MR, Grossberg G, Gauthier S, et al. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 2010; 26: 2441-7.
9. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
10. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
11. Panisset M, Roudier M, Saxton J, Boller F,. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994; 51: 41-5.
12. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S33-9.
13. Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005; 11: 446-53.
14. Rosen WG, Mohs RC, Davis KL,. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
15. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
16. Schmidt R, Alf C, Bancher C, et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatry 2009; 23: 58-63.
17. Han HJ, Lee JJ, Park SA, et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol 2011; 7: 137-42.
18. Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011; 65: 790-6.
19. Greenspoon J, Herrmann N, Adam DN,. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. CNS Drugs 2011; 25: 575-83.
20. Hurkmans JF, Bodde HE, van Driel LM, et al. Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application. Br J Dermatol 1985; 112: 461-7.
21. Farage MA, Miller KW, Berardesca E, Maibach HI,. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10: 73-86.
22. Emre M, Bernabei R, Blesa R, et al. Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010; 16: 246-53.